Innate Pharma (IPHA) said Monday its investigational new drug application has been cleared by the US Food and Drug Administration for a phase 1 trial of IPH4502, an antibody drug conjugate targeting Nectin-4 in solid tumors.

The trial, to start in coming months, will include dose escalation and optimization sections and will assess the safety, tolerability and preliminary efficacy of IPH4502 as a single agent, the company said.

Innate Pharma shares were more than 7% higher in premarket trading.

Price: 2.2600, Change: +0.15, Percent Change: +7.11